Targeting Cellular Signalling Pathways in Lung Diseases

個数:

Targeting Cellular Signalling Pathways in Lung Diseases

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 926 p.
  • 言語 ENG
  • 商品コード 9789813368293
  • DDC分類 616.24

Full Description

The book comprehensively reviews and provides detailed insight into the cellular and molecular signalling mechanisms involved in pathophysiology of various respiratory diseases, towards developing effective therapeutic strategies in the management and treatment of lung disease. It also covers promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing the disease features including novel strategies for targeting chronic lung diseases using advanced drug delivery systems. Importantly, the book examines the significance and relevance of the plant extracts and their constituents with therapeutic efficiencies against lung diseases. As such, the book offers a blend of translational, biological, chemical, and drug delivery aspects relevant to respiratory diseases, thus, offering a valuable resource for pulmonologists and translational researchers working in the field of pulmonary biology and respiratory medicine.

Contents

Chapter 1. Introduction to Lung Diseases.- Chapter 2. Targeting molecular and cellular mechanisms in asthma.-Chapter 3. Various cellular and molecular axis involved in the pathogenesis of asthma.- Chapter 4. Targeting molecular and cellular mechanisms in steroid resistant asthma.- Chapter 5. Targeting molecular and cellular mechanisms in chronic obstructive pulmonary disease.- Chapter 6. Probing the cellular and molecular mechanisms underlying in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD).- Chapter 7. Chronic obstructive pulmonary disease: Molecular basis of pathogenesis and targeted therapeutic approaches.- Chapter 8. Exploring the 'dormancy-activation switch' in the tumour microenvironment for metastatic lung cancer: The possible role of microRNA.- Chapter 9. Therapeutic strategies targeting signalling pathways in lung cancer.- Chapter 10. Modulation of signalling pathways byimmunotherapeutics in lung cancer.- Chapter 11. Underpinning the Cellular and Molecular Mechanisms with Nanotheronstics for Lung Cancer.- Chapter 12. Targeting molecular and cellular mechanisms in Idiopathic Pulmonary Fibrosis.-Chapter 13. A refined approach to target the molecular and cellular mechanisms in pulmonary fibrosis.-Chapter 14. Targeting molecular and cellular mechanisms in tuberculosis.- Chapter 15. Cellular and Molecular Mechanisms of Repurposed antidiabetic drug as adjunctive treatment for tuberculosis.- Chapter 16. Targeting host and bacterial signaling pathways in tuberculosis: An effective strategy for the development of novel anti-tubercular therapies.- Chapter 17. Targeting molecular and cellular mechanisms in pulmonary hypertension.- Chapter 18. Targeting molecular and cellular mechanisms in pulmonary arterial hypertension.- Chapter 19. Potential cellular targets associated with the signaling and therapeutics of the pulmonary hypertension.- Chapter 20. Targeting molecular and cellular mechanisms in influenza A virus infections.- Chapter 21. Understanding the Biology of Non-typeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease through the Lens of Genomics.- Chapter 22. Targeting molecular and cellular mechanisms in rhinovirus infection.- Chapter 23. Targeting molecular and cellular mechanisms in respiratory syncytial virus (RSV) infection.- Chapter 24. Targeting molecular and cellular mechanisms SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 25. Underpinning the rudimentary mechanisms involved in the pathogenesis of SARS-CoV2 (COVID-19) in human lung cells.- Chapter 26. Targeting molecular and cellular mechanisms in SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 27. Special features of human lung ACE2 sensitivity to SARS CoV-2 spike glycoprotein.- Chapter 28. Implications of Phosphoinositide 3-kinase (PI3K) Signalling in cellular and molecular mechanisms of respiratory diseases.- Chapter 29. The role of the cholinergic system in lung diseases.- Chapter 30. The Nrf2-Keap1 signaling pathway in lung cancer.- Chapter 31. Role of Toll like receptor (LTR) in molecular and cellular mechanism of respiratory diseases.- Chapter 32. Biomarkers of Oxidative Stress.- Chapter 33. Targeting chronic lung diseases using advanced drug delivery systems.- Chapter 34. Plant based chemical moieties targeting cellular signalling pathways in chronic lung diseases.- Chapter 35. Role of phytoconstituents in targeting cytokines for managing pathophysiology of lung diseases.- Chapter 36. Targeting Cellular Signaling Pathways in Lung Cancer and Role of Phytochemicals as Novel Therapeutic Approach.- Chapter 37. Natural compounds targeting major signalling pathways in lung cancer.- Chapter 38. Drug delivery in respiratory diseases: Current opportunities,  Molecular and cellular mechanism, and Future challenges.- Chapter 39. Future prospects and challenges in targeting cellular and molecular mechanisms in respiratory diseases.

最近チェックした商品